Silence Therapeutics Plc American Depository Share (SLN)

Nasdaq: SLN · Pharmaceutical Preparations · London · filing with the SEC since 2010

Full chart Alerts Compare

Grade3.4

◀ Past 5.0● Present 2.2▶ Future 3.4

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$559,000-98.7%

Net income-$88.6M-95.6%

Earnings per share$-0.63-90.9%

Operating cash flow-$62.3M+7.9%

Cash$11.3M-90.7%

Debtn/a

Shareholders’ equity$62.3M-53.5%

Shares, diluted141.7M+2.1%

Return on equity-142.2%

The recordfrom its filings

Filings in 202647

Newest filingNov 13 · 10-Q

Annual reportMar 5, 2026

Quarterly reportNov 13, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents grantedn/a

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $456,000Net income -$51.4MCash from operations -$44.1Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

22232425

As filed, in USD. Nothing here is a forecast.

News

Nov 13, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Silence Therapeutics Plc American Depository Share is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in London.

Newest on the record

Quarterly report on Nov 13. Before it, large holder update, amended on Nov 12.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About SLN

Silence Therapeutics Plc American Depository Share is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in London. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $559 thousand and a loss of $89 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersLondon

Business modelPre-revenue company

ExchangeNasdaq, OTC

Filing since2010

SEC number (CIK)1479615

Peers on fileCTXR, ACRV, MCRB, MNPR

Who runs it

Financial performance

In fiscal 2025 Silence Therapeutics Plc American Depository Share’s revenue was $559,000, down 98.7% from $43.26 million the year before. It made a net loss of $88.61 million.

Annual report, filed Mar 5, 2026.

Financial statements

The grade

Silence Therapeutics Plc American Depository Share grades 3.4 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past5.0

● Present2.2

▶ Future3.4

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton SLN · research, not advice